SANTA CRUZ, CA, Capstan Medical, a developer of robotic-enabled minimally invasive solutions to address heart valve disease, announced the successful closing of an oversubscribed $110 million Series C.
Capstan Medical, a developer of robotic-enabled minimally invasive solutions to address heart valve disease, announced the successful closing of an oversubscribed $110 million Series C to further advance its mission of bringing its innovative structural heart solution to patients. The round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
(c) by Massinvestor, Inc. For contact info, please check out our about page.